Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis - PubMed
3 hours ago
- #tirzepatide
- #cardiovascular outcomes
- #type 2 diabetes
- Tirzepatide significantly reduces major adverse cardiovascular events (MACE), CV mortality, all-cause mortality, non-fatal MI, and non-fatal stroke compared to placebo in patients with type 2 diabetes.
- Tirzepatide shows comparable efficacy to individual GLP-1 receptor agonists (GLP-1RAs) in cardiovascular risk reduction.
- The study is a systematic review and network meta-analysis of 11 trials, including the SURPASS-CVOT trial for tirzepatide.
- Subgroup and sensitivity analyses confirmed the robustness of the findings.
- Tirzepatide's dual GIP/GLP-1 receptor agonist mechanism may offer cardiovascular benefits at least comparable to established GLP-1RAs.